登录

Wyss Zurich扩大投资组合

Wyss Zurich expands portfolio

startupticker | 2024-04-19 | 翻译由动脉网AI生成,点击反馈

可切换为仅中文


Tandem Therapeutics has entered the Wyss Zurich program, joining MYNERVA and Tethys which were accepted in the past six months. With CHF 120+ million already invested in all projects since 2018, the program will provide the new entrants with funding, access to infrastructure and expert support to fuel their project development..

Tandem Therapeutics已加入Wyss-Zurich计划,加入了MYNERVA和Tethys,在过去六个月内被接受。自2018年以来,所有项目已投资1.2亿多瑞士法郎,该项目将为新加入者提供资金、基础设施和专家支持,以推动其项目发展。。

Wyss Zurich is a joint accelerator of the University of Zurich and ETH Zurich, funded by a generous donation from the Swiss entrepreneur and philanthropist Dr Hansjörg Wyss. By providing projects with capital and access to infrastructure along with coaching and mentoring, the program expedites the research translation into new treatment protocols and clinical therapies, as well as novel technologies and intelligent systems.

Wyss Zurich是苏黎世大学和苏黎世理工大学的联合加速器,由瑞士企业家和慈善家Hansjörg Wyss博士的慷慨捐赠资助。通过为项目提供资金和基础设施,以及辅导和指导,该项目加速了研究转化为新的治疗方案和临床疗法,以及新技术和智能系统。

Focus areas are in the emerging fields of regenerative medicine, robotics, and medical devices/bionics..

重点领域是再生医学、机器人和医疗设备/仿生学等新兴领域。。

Since the launch in 2015, Wyss Zurich has supported 25 projects, many of which have transformed into startups and created over 700 jobs. The projects have received CHF 120 million through the program and went on to secure an additional CHF 270 million in financing rounds.

自2015年启动以来,Wyss Zurich已支持25个项目,其中许多项目已转型为初创公司,并创造了700多个就业岗位。这些项目通过该计划获得了1.2亿瑞士法郎,并在融资回合中获得了另外2.7亿瑞士法郎。

Over the past six months, three new projects joined the program. Tandem Therapeutics, with its project aimed at developing novel peptide drug conjugates to precision target and treat fibrosis-driven diseases, is the newest of them.  Fibrosis represents a significant unmet medical challenge, contributing to over 45% of deaths in the developed world.

在过去的六个月里,三个新项目加入了该计划。串联疗法(Tandem Therapeutics)是其中最新的一个,其项目旨在开发新型肽-药物偶联物,以精确靶向和治疗纤维化驱动的疾病。纤维化是一个尚未解决的重大医学挑战,导致发达国家超过45%的死亡。

Progressive fibrosis leads to the disruption of organ function and represents a significant cause of morbidity and mortality globally. Using a deep understanding of matrix mechanobiology and its relation to disease progression, Tandem Therapeutics is developing a pipeline of selectively targeted, efficacious, and safe therapies to treat progressive lung fibrosis..

进行性纤维化导致器官功能的破坏,是全球发病率和死亡率的重要原因。通过深入了解基质机械生物学及其与疾病进展的关系,Tandem Therapeutics正在开发一系列选择性靶向,有效和安全的治疗方法来治疗进行性肺纤维化。。

Mynerva and Tethys Robotics have been with Wyss Zurich for the last six months. Founded by Greta Preatoni, Mynerva is developing a wearable neuro-stimulating medical device in the form of a shoe sole to reduce chronic pain and to restore the sense of touch in patients suffering from diabetic neuropathy.

Mynerva和Tethys Robotics在苏黎世Wyss工作了六个月。Mynerva由Greta Preatoni创立,目前正在开发一种可穿戴的神经刺激医疗设备,其形式为鞋底,以减轻慢性疼痛并恢复糖尿病神经病变患者的触觉。

Thanks to the technologies potential to transform lives for millions of people worldwide, Mynerva has stood out in several competitions, winning over 27 prizes and awards since embarking on their journey..

由于技术潜力可以改变全世界数百万人的生活,Mynerva在几场比赛中脱颖而出,自踏上征程以来,已获得27项奖项。。

In the robotics segment, Tethys Robotics is developing a compact and autonomous underwater drone for automated inspection and assessments in rough waters. Tasks around underwater operations such as conducting critical inspections and interventions are conducted by human divers who expose themselves to vast risks, especially in turbulent waters.

在机器人领域,特提斯机器人公司(Tethys robotics)正在开发一种紧凑、自主的水下无人机,用于在崎岖的水域进行自动检查和评估。围绕水下作业的任务,例如进行关键检查和干预,是由人类潜水员进行的,他们将自己暴露在巨大的风险中,尤其是在动荡的水域中。

Current robotic solutions lack the necessary robustness in key metrics required for harsh aquatic environments, or necessitate costly, environmentally polluting vessels and infrastructure. Tethys drone solution addresses these limitations, enabling autonomous mapping and survey even in strong water flows and poor visibility.

目前的机器人解决方案在恶劣的水生环境所需的关键指标方面缺乏必要的稳健性,或者需要昂贵的、污染环境的船只和基础设施。特提斯无人机解决方案解决了这些限制,即使在水流湍急和能见度较差的情况下也能进行自主测绘。

It even provides high resolution 3D models of submerged infrastructure.(RAN).

它甚至提供了水下基础设施的高分辨率3D模型。(跑了)。

0Comments

0注意事项

Back to all news

返回所有新闻

Please login

请登录

or sign up

或注册

to comment.

发表评论。

Commenting guidelines

评论指南

Send

发送

推荐阅读

这一医科大学

思宇MedTech 2024-05-19 00:29

华东医药:旗下3款“重磅进口”医美产品“国内临床”取得新进展

医美部落 2024-05-19 00:04

eGastroenterology:肠炎久不愈,益生元来助力

MedSci 2024-05-19 00:02

startupticker

94篇

最近内容 查看更多

AI基因数据分析软件平台SOPHiA GENETICS获得5000万美元债务融资

2024-05-14

自我检测试剂盒开发商Testmate Health获得600万美元种子轮融资,用于家庭STI测试

2024-05-03

生物技术行业的成功与挫折

2024-05-01

产业链接查看更多

所属赛道

医疗机器人
近30天,融资3起